Samsung has been able to roll out its advanced health monitoring features to a large number of new countries, post the European approval. Earlier only South Korea and the US had received approval for the use of the ECG and blood pressure monitoring for the Galaxy Watch 3 and Active 2 Smartwatches.
The list of countries that can use this feature include Austria, Belgium, Bulgaria, Croatia, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Netherlands, Norway, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, Switzerland, and the United Kingdom. They will receive the new feature on 4 February. In addition to Europe, Chile, UAE, Indonesia, India, Japan and China are also on the list but we are not sure of the roll out date yet for these countries. ECG feature has been a bone of contention in the smartwatch space with Apple leading and Fitbit following close with its Fitbit Sense. Blood pressure is less popular with Samsung leading this space. This feature, however, requires validation against a traditional cuff on a regular basis. Blood pressure monitoring may be very useful for hypertension sufferers, but it may not become a coveted consumer metric.
The Aktiia band is launching in Europe as it has received CE clearance as a Grade II medical device. It can track blood pressure from a PPG sensor without validation. There is also a rumour that Samsung might add a non-invasive glucose tracking feature in 2021. Visit this space to check if this is a mere rumour or we can hope to see this feature on a Galaxy Watch 4 or Active 3.